Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | UBE2N | P61088 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 14/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964208 | 0.89 | S1PR1 (0.56) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1964561 | 0.89 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1964962 | 0.88 | S1PR1 (0.64) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1964560 | 0.88 | S1PR1 (0.51) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1966161 | 0.85 | S1PR1 (0.68) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1971713 | 0.84 | S1PR1 (0.71) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1968240 | 0.83 | S1PR1 (0.67) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1969999 | 0.83 | HSD17B10 (0.56) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1966270 | 0.83 | S1PR1 (0.76) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL1966944 | 0.82 | S1PR1 (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | claimed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | claimed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| EP-2334670-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | Almirall S.A. (ES) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | S1PR2, S1PR3, S1PR1 | KDM4E 4607/4885ALDH1A1 1610/4885SMN1; SMN2 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.